优化心房的管理,使用一种新的患者级计算模型.
Minsi Cai1, Cristian Barrios-Espinosa2, Michiel Rienstra3
1Department of Cardiology, Cardiovascular Research Institute Maastricht, Faculty of Health, Medicine, and Life Sciences, Maastricht University, Maastricht, the Netherlands.
Med (New York, N.Y.)
|November 1, 2025
概括
早期检测心房动 (AF) 是一个挑战. 频繁的查改善了AF检测,但中风的减少取决于患者和医疗保健因素,每天三次心电图显示的最高率.
科学领域:
- 心血管疾病中的计算建模.
- 卫生信息学和预测分析.
- 心房动的流行病学
背景情况:
- 由于剧情变化和症状相关性差,早期检测心房 (AF) 很困难.
- 对AF的最佳查策略及其对中风预防的影响仍然不清楚.
研究的目的:
- 用计算模型分析了查介导的AF检测对中风风险的影响.
- 评估不同查策略对早期AF诊断和中风风险调节的有效性.
主要方法:
- 一个类似马尔科夫的计算机模型模拟了七种临床状态和AF相关的心房重塑.
- 模型校准和验证是通过复制临床研究来进行的.
- 该模型评估了查策略对AF诊断的影响,并模拟了口服抗凝剂对中风率的影响.
主要成果:
- 该模型准确地模拟了患者一生的AF情节和临床结果.
- 间歇性AF查的好处取决于频率和持续时间;每天三次的ECG产生了最高的检测率.
- 查组显示了可比的5年和较低的25年中风率,其益处被有效的抗凝药和更高的基线中风风险放大.
结论:
- 开发了一种新的患者水平的计算AF模型,与真实世界的数据一致.
- 该模型允许对AF管理策略进行系统评估.
- 虽然频繁的查增加了AF的检测,但中风的减少取决于患者和医疗保健系统的特点.
相关概念视频
Dysrhythmias VI: Management of Dysrhythmias
424
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
424
Atherosclerosis III: Management
311
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
311
Aortic Regurgitation III: Medical Management
385
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
385
Cardiomyopathy III: Hypertrophic Cardiomyopathy
387
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
387
Heart Failure V: Medical Management
208
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
208


